Provided here are links that highlight relevant milestones and news for Juvabis.
For more up-to-date information, please visit our LinkedIn profile.
Juvabis announces positive Clinical Phase 1 results of EBL-1003 in the Innovative Medicines Initiative ENABLE Consortium.
Click here for Press Release on LinkedIn
24.11.2020
Interview with Founding CEO Dr Sven Hobbie as part of Antimicrobial Resistance campaign, World Antimicrobial Awareness Week, 2020
18.11.2020
A very promising new antibiotic just started clinical trials
Researchers from ENABLE are hopeful about EBL-1003 because it has passed the stage at which most potential antibiotics fail.
19.11.2019
